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Social play behavior is a highly rewarding, developmentally important form of
social interaction in young mammals. However, its neurobiological underpinnings
remain incompletely understood. Previous work has suggested that opioid and
endocannabinoid neurotransmission interact in the modulation of social play. Therefore,
we combined behavioral, pharmacological, electrophysiological, and genetic approaches
to elucidate the role of the endocannabinoid 2-arachidonoylglycerol (2-AG) in social play,
and how cannabinoid and opioid neurotransmission interact to control social behavior
in adolescent rodents. Systemic administration of the 2-AG hydrolysis inhibitor JZL184
or the opioid receptor agonist morphine increased social play behavior in adolescent
rats. These effects were blocked by systemic pretreatment with either CB1 cannabinoid
receptor (CB1R) or mu-opioid receptor (MOR) antagonists. The social play-enhancing
effects of systemic morphine or JZL184 treatment were also prevented by direct infusion
of the CB1R antagonist SR141716 and the MOR antagonist naloxone into the nucleus
accumbens core (NAcC). Searching for synaptic correlates of these effects in adolescent
NAcC excitatory synapses, we observed that CB1R antagonism blocked the effect of the
MOR agonist DAMGO and, conversely, that naloxone reduced the effect of a cannabinoid
agonist. These results were recapitulated in mice, and completely abolished in CB1R
and MOR knockout mice, suggesting that the functional interaction between CB1R and
MOR in the NAcC in the modulation of social behavior is widespread in rodents. The data
shed new light on the mechanism by which endocannabinoid lipids and opioid peptides
interact to orchestrate rodent socioemotional behaviors.
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INTRODUCTION
Social play behavior is a highly vigorous form of social
interaction, which is abundant in young mammals, including
humans (Panksepp et al., 1984; Pellis and Pellis, 2009). In terms
of structure, social play behavior contains elements of sexual,
aggressive, and affiliative behavior, but in an out-of-context
and modified, often exaggerated fashion (Panksepp et al., 1984;
Vanderschuren et al., 1997; Pellis and Pellis, 2009). Social play
is thought to facilitate neurobehavioral development (Pellis and
Pellis, 2009; Vanderschuren and Trezza, 2014), and abnormal
social play is observed in child and adolescent psychiatric
disorders (Alessandri, 1992; Jordan, 2003).
Social play has a strong rewarding value (Calcagnetti and
Schechter, 1992; Trezza et al., 2011b; Achterberg et al., 2016).
It can be used as an incentive for place conditioning, operant
conditioning and maze learning in laboratory animals (for a
review see Panksepp et al., 1987; Trezza et al., 2011a), and social
play is modulated by neurotransmitters implicated in reward
and motivation, such as endogenous opioids, endocannabinoids
(eCBs), and dopamine (Trezza and Vanderschuren, 2008b;
Trezza et al., 2010; Achterberg et al., 2016; Manduca et al.,
2016; Vanderschuren et al., 2016). The nucleus accumbens
(NAc) has been identified as an anatomical substrate for
motivation and reward (Everitt and Robbins, 2005; Berridge
and Kringelbach, 2015; Floresco, 2015). Indeed, the NAc has
been shown to be involved in social play behavior in rats
(Vanderschuren et al., 1995b; Gordon et al., 2002; Trezza
et al., 2011b, 2012; van Kerkhof et al., 2013, 2014; Manduca
et al., 2016). Notably, mu-opioid receptor (MOR) activation
in the NAc stimulates social play in adolescent rats (Trezza
et al., 2011b). Likewise, intra-NAc infusion of the dopamine
releaser/reuptake inhibitor amphetamine increases social play
behavior, and the social play-enhancing effects of increased
opioid and eCB neurotransmission depend on stimulation
of dopamine receptors in the NAc (Manduca et al., 2016).
Interestingly, with regard to the modulation of social play
by local opioid and dopamine signaling, there does not seem
to be a major difference between the NAc core (NAcC)
and shell subregions (Trezza et al., 2011b; Manduca et al.,
2016).
In the CNS, two principal eCBs are thought to be responsible
for the neuromodulatory functions of CB1 cannabinoid receptors
(CB1R): anandamide and 2-arachidonoylglycerol (2-AG; Katona
and Freund, 2012). Both molecules are synthesized on-demand
to regulate synaptic transmission (Castillo et al., 2012). Aberrant
eCB signaling in the NAc has been implicated in several
emotional disorders including anxiety, depression and addiction
(Kasanetz et al., 2010; Lafourcade et al., 2011; Jung et al., 2012).
Anandamide stimulates social play via CB1R located in the
basolateral amygdala and the NAc, whereby the former structure
appears to play a more prominent role (Trezza et al., 2012).
2-AG is known to regulate emotional behaviors in rodents
(Campolongo and Trezza, 2012; Mulvihill and Nomura, 2013)
and it mediates synaptic plasticity in limbic brain areas, such as
the NAc, the amygdala and the prefrontal cortex (Puente et al.,
2011; Katona and Freund, 2012).
CB1R and opioid receptors (OR) exhibit overlapping
mechanisms and they are likely interact to modulate multiple
behaviors (Navarro et al., 2001; Fattore et al., 2005; Mackie,
2005; Hudson et al., 2010; Pertwee, 2010; Befort, 2015) starting
at early developmental stages (Ellgren et al., 2007, 2008;
Biscaia et al., 2008; Naudon et al., 2013). Indeed, opioid and
eCB neurotransmission have been shown to interact in the
modulation of social play (Trezza and Vanderschuren, 2008a,
2009), but it is not known whether this interaction occurs
at the level of the NAc. Moreover, the contribution of the
endocannabinoid, 2-AG, to social play remains unknown.
Here we combined behavioral, pharmacological,
electrophysiological and genetic methods to address these
questions. To test the role of 2-AG in social behavior in
adolescent rats and mice, we relied on the well-characterized
2-AG hydrolysis inhibitor JZL184, which prolongs the effects
of locally produced 2-AG (Long et al., 2009; Seillier et al., 2014;
Morena et al., 2015). We hypothesized that MORs and CB1Rs
interact in the modulation of social behavior in young rats and
mice.
MATERIALS AND METHODS
Animals
Rats and mice arrived in our animal facility at 3 weeks of age and
they were housed in groups of five under controlled conditions
(i.e., temperature 21 ± 1◦C, 60 ± 10% relative humidity and 12
h light/dark cycles). Food and water were available ad libitum.
All procedures were performed in agreement with the European
Communities Council Directive (2010/63/EU) for the Care and
Use of Laboratory Animals. For behavioral experiments, male
Wistar rats and male C57Bl6/J mice (age 4–6 weeks) were used.
For electrophysiological experiments, male Wistar rats (age 4–
6 weeks) were used for all experiments unless otherwise stated.
Female CB1R null mice (CB1R−/−) on a C57Bl6/J genetic
background (Sanchis-Segura et al., 2004; age 5–10 weeks) were
used to confirm cannabinoid dependent action of DAMGO, with
wild type (WT) littermates used as control group (CB1R+/+).
Female and male MOR receptor null mice (MOR−/−) on a 50%
C57Bl6/J and 50% 129SvPAS genetic background (Matthes et al.,
1996; age 4–7 weeks) were used to test MOR dependent action of
CP55940, with WT littermates as control group (MOR+/+).
Behavioral Experiments
Surgical Procedures
The surgical procedures were based on our previous experiments
(Trezza et al., 2011b, 2012; Manduca et al., 2016). At 4 weeks of
age, rats were anesthetized with sodium pentobarbital (35mg/kg,
i.p.; Sigma Aldrich, Italy) and positioned into a stereotaxic frame
(David Kopf Instruments, USA). Guide cannulae (24-gauge;
Cooper’s Needleworks, UK) were implanted bilaterally, aimed
1.0mm above the NAcC (coordinates: AP + 1.5mm; ML ±
1.9; DV − 6.5mm (Trezza et al., 2011b, 2012). Cannulae were
secured with stainless steel screws and dental acrylic; 29-gauge
wire stylets (Cooper’s Needleworks, UK) were inserted into the
guide cannulas to maintain patency. After surgery, the rats were
individually housed and allowed to recover for 4 days. On the
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fifth day, they were re-housed in groups of five with their original
cage mates. Behavioral testing began 1 week after surgery.
Drugs and Infusion Procedures
The monoacylglycerol lipase (MAGL) inhibitor
JZL184 [4-[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-
1-piperidinecarboxylic acid 4-nitrophenyl ester] and
the CB1 receptor antagonist/inverse agonist SR141716
[N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-
4-methyl-1H-pyrazole-3-carboxamide hydrochloride; National
Institute of Mental Health’s (NIMH) Chemical Synthesis and
Drug Supply Program, USA] were dissolved in 5% Tween
80/5% polyethylene glycol/saline. The opioid receptor agonist
morphine (SALARS, Italy), the opioid receptor antagonist
naloxone hydrochloride (Sigma Aldrich, Italy) and the selective
µ-opioid receptor antagonist CTAP (D-Phe-Cys-Tyr-D-Trp-
Arg-Thr-Pen-Thr-NH2; Sigma Aldrich, Italy) were dissolved
in saline. JZL184 (1–5mg/kg) and morphine (1 mg/kg)
were given intraperitoneally (i.p.) and subcutaneously (s.c.)
2 and 1 h, respectively, before testing. For systemic drug
treatment experiments, SR141716 (0.1mg/kg, i.p.) and naloxone
hydrochloride (1mg/kg, s.c.) were injected 30min and 1 h
before JZL184 and morphine, respectively. For intracranial
drug treatment experiments, SR141716 (3µg/0.3 µl), naloxone
hydrochloride (0.5µg/0.3µl) and CTAP (0.3µg/0.3µl) were
infused into the NAcC immediately before testing. Dose ranges
were selected based on our previous studies (Trezza et al., 2011b,
2012) and pilot experiments (data not shown). Bilateral infusions
of drugs or an equivalent volume of the corresponding vehicle
were made as described in our previous studies (Trezza et al.,
2011b, 2012; Manduca et al., 2016). After infusions, animals
were left in a holding cage for 5min before testing. At the end
of experiments, injection sites were confirmed histologically
according to the atlas of rat brain (Paxinos and Watson,
2007) as previously described (Trezza et al., 2011b, 2012).
Only pairs in which both animals had bilateral needle tracks
terminating into the NAcC were included in the final analysis.
For histological assessment of representative experiments see
Supplementary Figure 1.
Social Behavior in Adolescent Rats and Mice
The experiments were performed in a sound attenuated chamber
under dim light conditions. The testing arena consisted of a
Plexiglas cage measuring 40 × 40 × 60 cm3 (l × w × h) with
2 cm of wood shavings covering the floor. Social behavior was
assessed as previously described (Terranova and Laviola, 2005;
Trezza et al., 2011b, 2012; Janecka et al., 2015).
To evaluate (1) the effects of systemic administration of
JZL184 on social play behavior (Figures 1A,B, 4A,B) and
(2) whether the effects of JZL184 were mediated by CB1R
(Figures 1C,D, 4C,D) and/or OR activation (Figures 2C,D,
4E,F), adolescent rats and mice (that had not undergone
stereotaxic surgery) were individually habituated to the test
cage for 10 min on each of the 2 days before testing. Before
testing, adolescent rats were socially isolated for 3.5 h to enhance
their social motivation and thus facilitate the expression of
social play behavior during testing (Niesink and Van Ree, 1989;
FIGURE 1 | 2-AG elevation stimulates social play via CB1R in the NAcC
in adolescent rats. JZL184 (1 mg/kg, i.p.) enhanced pinning (A) and
pouncing (B) frequency. Systemic pretreatment with the CB1R antagonist
SR141716 (0.1 mg/kg, i.p.) blocked the effects of JZL184 on pinning (C) and
pouncing (D). Intra-NAcC infusion of SR141716 (3µg/0.3µl) antagonized the
play-enhancing effects of JZL184 (1 mg/kg, i.p.) (E,F). Data represent
mean ± S.E.M. frequency of pinning and pouncing. *p < 0.05, **p < 0.01,
***p < 0.001 vs. vehicle; $p < 0.05, $$p < 0.01 vs. vehicle/JZL184
(Student-Newman-Keuls post-hoc test). N = 7–9 per treatment group.
Vanderschuren et al., 1995a, 2008). The test consisted of placing
the animal together with a similarly treated partner into the test
cage for 15 min (rats) or 10 min (mice). To determine whether
the increase in social play induced by JZL184 depends upon
activation of CB1R (Figures 1E,F) and/or MOR (Figures 2E,F)
in the NAcC, rats equipped with bilateral guide cannulae were
habituated to the experimental procedures on 2 consecutive days,
as previously described (Trezza et al., 2011b; van Kerkhof et al.,
2013; Manduca et al., 2016). On the first habituation day, they
were individually placed into the test cage for 10 min, and on
the second habituation day, they were isolated for 2 h. Pairs of
rats were then infused with saline solution and placed into the
test cage for 15 min to habituate them to the infusion procedures
and determine baseline levels of social play behavior. On the test
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FIGURE 2 | MOR activation in the NAcC is necessary for the 2-AG
induced stimulation of social play in adolescent rats. Play-enhancing
effects of morphine (1mg/kg, s.c.) were prevented by intra-NAcC infusion of
SR141716 (3µg/0.3µl) (A,B). Systemic pretreatment with the OR antagonist
naloxone (NLX: 1 mg/kg, s.c.) blocked the effects of JZL184 (1mg/kg, i.p.) on
pinning (C) and pouncing (D). Intra-NAcC infusion of NLX (0.5µg/0.3µl)
antagonized the play-enhancing effects of JZL184 (1mg/kg, i.p.) (E,F). Data
represent mean ± S.E.M. frequency of pinning and pouncing. *p < 0.05;
**p < 0.01, ***p < 0.001 vs. vehicle; $p < 0.05, $$p < 0.01, $$$p < 0.001 vs.
vehicle/JZL184 and vehicle/morphine (Student-Newman-Keuls post-hoc test).
N = 6–12 per treatment group.
day, the animals were isolated for 2 h before testing. Pairs of
rats were then infused simultaneously with either vehicle or drug
solutions and placed into the test cage for 15min. Behavior was
assessed per pair of animals and analyzed by a trained observer
who was unaware of the treatment condition, using the Observer
3.0 software (Noldus Information Technology, TheNetherlands).
Both animals in a test pair received the same treatment. Animals
in a test pair did not differ by >10 g in body weight and had
no previous common social experience (i.e., they were not cage
mates).
In adolescent rats, the following parameters were scored per
pair of animals: 1/frequency of pinning: one animal lying with
FIGURE 3 | 2-AG elevation stimulates social play via MOR in the NAcC
in adolescent rats. Intra-NAcC infusion of the selective MOR antagonist
CTAP (0.3µg/0.3µl) prevented the increase in pinning (A) and pouncing (B)
induced by systemic treatment with JZL184 (1 mg/kg, i.p.). Data represent
mean ± S.E.M. frequency of pinning and pouncing. *p < 0.05 vs. vehicle; $p
< 0.05 vs. vehicle/JZL184 (Student-Newman-Keuls post-hoc test). N = 7–9
per treatment group.
its dorsal surface on the floor with the other animal standing
over it. This is the most characteristic posture in social play in
rats; it occurs when one animal is solicited to play by its test
partner and rotates to its dorsal surface (Panksepp and Beatty,
1980; Pellis and Pellis, 2009; Trezza et al., 2010); 2/frequency of
pouncing: one animal is soliciting the other to play, by attempting
to nose or rub the nape of its neck (Panksepp and Beatty, 1980;
Pellis and Pellis, 2009; Trezza et al., 2010). In addition to these
measures, time spent in social exploration (sniffing, licking, or
grooming any part of the body of the test partner, including the
anogenital area) was also assessed as a measure of general social
interest; this may not necessarily be associated with playful social
behavior.
In adolescent mice, the total time and total frequency of active
social interactions were obtained as the sum of the time and
frequency of social sniffing (sniffing any part of the body of the
test partner), social grooming (one mouse licks and chews the fur
of the conspecific, while placing its forepaws on the back or the
neck of the other mouse), following/chasing (walking or running
in the direction of the partner which stays where it is or moves
away), crawling under/over (one animal crawls underneath or
over the partner’s body, crossing it transversely from one side
to the other) scored per 10 min (Terranova and Laviola, 2005;
Janecka et al., 2015) (for the experimental design see Table 1).
Because of its reciprocal nature, we studied social behavior
as a dyadic interaction, i.e., we considered a pair of animals as
an experimental unit. Therefore, we used pairs of animals of the
same sex, age, and weight and both animals in a pair received the
same treatment.
Physiology
Slice Preparation
Animals were anesthetized with halothane (rats) or isoflurane
(mice) and decapitated according to institutional regulations.
The brain was sliced (300µm) in the coronal plane with a
vibratome (Integraslice, Campden Instruments, Loughborough,
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UK) in a sucrose-based solution at 4◦C (in mM: 87 NaCl, 75
sucrose, 25 glucose, 2.5 KCl, 4 MgCl2, 0.5 CaCl2, 23 NaHCO3,
and 1.25 NaH2PO4). Immediately after cutting, slices were stored
for 1 h at 32◦C in a low calcium artificial cerebrospinal fluid (low
Ca2+ ACSF) that contained in mM: 130 NaCl, 11 Glucose, 2.5
KCl, 2.4 MgCl2, 1.2 CaCl2, 23 NaHCO3, 1.2 NaH2PO4, and was
equilibrated with 95%O2/5% CO2 and then at room temperature
until the time of recording.
Electrophysiology
Whole cell patch-clamp of visualized medium spiny neurons
(MSN) and field potential recordings were made in coronal
slices containing the ventral striatum as previously described
(Robbe et al., 2002). Recordings were made in the medial
ventral NAcC close to the anterior commissure (Robbe et al.,
2002). For extracellular field experiments (fEPSP), the recording
pipette was filled with ACSF. Both the fEPSP amplitude and
TABLE 1 | Behavioral experimental design.
Treatment Mechanism of action Animal species used Group treatment Way of injection
Systemic JZL184 administration
(Figures 1A,B, 4A,B)
By enhancing 2-AG levels, systemic
administration of JZL184 increased social
play behavior in rats and mice
Rats Control systemic (i.p.)
JZL184 1 mg/kg systemic (i.p.)
JZL184 5 mg/kg systemic (i.p.)
Mice Control systemic (i.p.)
JZL184 4 mg/kg systemic (i.p.)
JZL184 8 mg/kg systemic (i.p.)
JZL184 16 mg/kg systemic (i.p.)
Systemic JZL184 + SR141716
administration (Figures 1C,D,
4C,D)
Pretreatment with the CB1R antagonist
SR141716 blocked the JZL184
play-enhancing effects on social play
behavior in rats and mice
Rats Control systemic (i.p.)
JZL184 1 mg/kg systemic (i.p.)
SR141716 0.1 mg/kg systemic (i.p.)
SR 0.1 mg/kg + JZL184 1 mg/kg systemic (i.p.)
Mice Control systemic (i.p.)
JZL184 8 mg/kg systemic (i.p.)
SR141716 3 mg/kg systemic (i.p.)
SR 3mg + JZL184 8 mg/kg systemic (i.p.)
Intra-NAcC SR141716 after
systemic administration of
JZL184 (Figures 1E,F)
Intra-NAcC infusion of the CB1R
antagonist SR141716 blocked
play-enhancing effects of systemic
JZL184 treatment in rats
Rats Control Intra NAcC
JZL184 1mg systemic (i.p.)
SR141716 3µg Intra NAcC
SR 3µg + JZL184 1 mg/kg Intra NAcC +
systemic (i.p.)
Intra-NAcC SR141716 after
systemic administration of
morphine (Figures 2A,B)
Intra-NAcC infusion of the CB1R
antagonist SR141716 blocked the
play-enhancing effects of systemic
treatment with the opioid receptor agonist
morphine in rats
Rats Control Intra NAcC
MOR 1 mg/kg systemic (s.c.)
SR141716 3µg Intra NAcC
SR 3µg + MOR 1mg/kg Intra NAcC +
systemic (s.c.)
JZL184 + naloxone systemic
administration (Figures 2C,D,
4E,F)
Pretreatment with the OR antagonist
naloxone blocked the play-enhancing
effects of systemic treatment with JZL184
in rats and mice
Rats Control systemic (i.p.)
JZL184 1mg/kg systemic (i.p.)
NLX 1mg/kg systemic (s.c.)
NLX 1mg/kg + JZL184 1 mg/kg systemic (s.c.) +
systemic (i.p.)
Mice Control systemic (i.p.)
JZL184 8 mg/kg systemic (i.p.)
NLX 1 mg/kg systemic (s.c.)
NLX 1 mg/kg + JZL184 8 mg/kg systemic (s.c.) +
systemic (i.p.)
Intra-NAcC naloxone after
systemic administration of
JZL184 (Figures 2E,F)
Intra-NAcC infusion of the OR antagonist
naloxone blocked the play-enhancing
effects of systemic treatment with JZL184
in rats
Rats Control Intra NAcC
JZL184 1 mg/kg systemic (i.p.)
NLX 0.5µg Intra NAcC
NLX 0.5µg + JZL184 1 mg/kg Intra NAcC +
systemic (i.p.)
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area were measured (graphs depict amplitudes). For recording,
slices were placed in the recording chamber and superfused
(1.5–2ml/min) with ACSF (same as low Ca2+ ACSF with the
following exception: 2.4 mM CaCl2 and 1.2mM MgCl2). All
experiments were done at 32◦C. Stimulation was performed
with a glass electrode filled with ACSF and placed ∼200µm in
the dorsal-medial direction of the recorded cell. The stimulus
(100µs duration) intensity was adjusted around 60% of maximal
intensity after performing an input-output curve (baseline
EPSC amplitudes ranged between 50 and 150 pA). Stimulation
frequency was set at 0.1 Hz. The extracellular fEPSP was
confirmed to be glutamatergic by application at the end of the
experiments of the non-NMDA ionotropic glutamate receptor
antagonist, DNQX (20µM), completely blocking the synaptic
component (Robbe et al., 2001, 2002, 2003). The superfusion
medium contained picrotoxin (100µM) to block gamma-
aminobutyric acid type A (GABA-A) receptors. All drugs were
added at the final concentration to the superfusion medium.
For whole cell patch-clamp experiments, neurons were visualized
using an upright microscope with infrared illumination. The
intracellular solution was based on K+ gluconate (in mM: 145
K+ gluconate, 3 NaCl, 1 MgCl2, 1 EGTA, 0.3 CaCl2, 2 Na
+
2 ATP,
and 0.3 Na+ GTP, 0.2 cAMP, buffered with 10 HEPES). Electrode
resistance was 4–6 MOhms. Whole cell patch-clamp recordings
were performed with an Axopatch-200B amplifier. Data were low
pass filtered at 2 kHz, digitized (10 kHz, DigiData 1440A, Axon
Instrument), collected using Clampex 10.2 and analyzed using
Clampfit 10.2 (all fromMolecular Device, Sunnyvale, USA). A−2
mV hyperpolarizing pulse was applied before each evoked EPSC
in order to evaluate the access resistance and those experiments
in which this parameter changed >25% were rejected. Access
resistance compensation was not used and acceptable access
resistance was <30 MOhms. The potential reference of the
amplifier was adjusted to zero prior to breaking into the cell.
Miniature EPSC were recorded from MSN clamped at −70mV.
Lidocaine (500µM) was added to block voltage gated Na2+
channels and absence of response to stimuli confirmed for a
minimum of 10min before recording used to calculate mEPSC
amplitude and frequency (Robbe et al., 2001).
Drugs
The GABA-A receptor antagonist picrotoxin, the MOR agonist
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) and
the MOR antagonist CTAP were from Sigma (France). The
non-NMDA ionotropic glutamate receptor antagonist DNQX
(6,7-dinitroquinoxaline-2,3-dione), the CB1R agonist CP55940
[2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-
5-(2-methyloctan-2-yl)phenol], the CB1R antagonist/inverse
antagonist AM251 [1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-
4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide], the OR
antagonist naloxone and the Na+ channel blocker lidocaine were
from Tocris (Bristol, UK). Other chemicals were of the highest
commercial grade available.
Statistical Analysis
All values are given as mean ±S.E.M. For electrophysiology
experiments, N corresponds to the number of animals tested for
each condition; for the behavioral experiments, N corresponds
to the pair of animals per treatment group. Electrophysiological
data were analyzed using Clampfit 10 (Molecular Devices,
Sunyvale, USA). The magnitude of plasticity was calculated
by 30–40 min after drug injection as percentage of baseline
responses. Behavioral data were analyzed using either one-way
or two-way ANOVA, followed by Student-Newman-Keuls post-
hoc test. Statistical analyses were performed using GraphPad
Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) and IBM
SPSS Statistics 20 (IBM, New York, NY, USA). Differences were
considered significant for p < 0.05.
RESULTS
2-AG Acting on CB1R Located in the NAcC
Stimulates Social Play in Adolescent Rats
Systemic administration of the 2-AG hydrolysis inhibitor JZL184
markedly increased social play in adolescent rats [one-way
ANOVA: pinning, F(2, 21) = 13.981, p < 0.001, Figure 1A;
pouncing, F(2, 21) = 10.190, p < 0.001; Figure 1B], without
affecting social exploration (Table 2). Post-hoc analysis revealed
that low doses of JZL184 (1 mg/kg) increased pinning
(Figure 1A) and pouncing (Figure 1B) frequency. These play-
enhancing effects were blocked following systemic pretreatment
with the CB1R antagonist SR141716 (0.1 mg/kg) 30 min
before systemic JZL184 [1mg/kg; two-way ANOVA: pinning,
F(JZLxSR) (1, 23) = 6.362, p < 0.05; Figure 1C; pouncing,
F(JZLxSR) (1, 23) = 7.749, p < 0.05; Figure 1D; for complete
statistical analysis see Table 3]. Post-hoc analysis revealed that
JZL184 (1mg/kg) increased social play when co-administered
with vehicle but not when the animals were pretreated with
SR141716. The most parsimonious interpretation of these data
is that 2-AG acts on CB1R to stimulate social play.
Next, we tested whether the effect of JZL184 on social play
was mediated through the NAcC. We found that intra-NAcC
infusion of SR141716 antagonized the play-enhancing effects
of systemic JZL184 [1 mg/kg; two-way ANOVA: pinning,
F(JZLsyst×SR NAcC) (1, 23) = 5.496, p < 0.05; Figure 1E; pouncing,
F(JZLsyst x SR NAcC) (1, 23) = 4.871, p < 0.05; Figure 1F; for
complete statistical analysis see Table 3]. Post-hoc analysis
showed that 2-AG elevation stimulates social play in adolescent
rats via CB1R located in the NAcC. Thus, elevation of 2-
AG stimulates social play by activating CB1R located in
the NAcC.
MOR Stimulation in the NAcC is Necessary
for the Play-Enhancing Effect of JZL184
Our previous work has shown that systemic CB1R antagonism
reduced the social play-enhancing effects of the MOR agonist
morphine (Trezza and Vanderschuren, 2008a). In light of the
present results, we tested whether intra-NAcC CB1R are involved
in the increase in social play induced by systemic administration
of morphine. Strikingly, we found that the morphine-induced
increase in social play was prevented by NAcC CB1Rs [two-
way ANOVA: pinning, F(MORsyst×SR NAcC) (1, 33) = 8.694,
p < 0.01; Figure 2A; pouncing, F(MORsyst×SR NAcC) (1, 33)
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TABLE 2 | Statistical report of social exploration duration in social play behavior in adolescent rats.
Treatment No. of animals for
group
Mean SEM Test ANOVA P-value
JZL184 systemic administration
(Figures 1A,B)
Control (n = 8) 248.581 24.130 One-way
ANOVA
F = 0.485 P = 0.621
JZL184 1mg (n = 9) 239.708 18.490
JZL184 5mg (n = 7) 269.467 21.921
JZL184 + SR141716 systemic
administration (Figures 1C,D)
Control (n = 7) 183.630 11.242 Two-way
ANOVA
TreatSR TreatJZL184 TreatSRxJZL184
JZL184 1mg (n = 7) 228.161 22.462 F = 2.060 F = 4.553 F = 0.633
SR141716A 0.1mg
(n = 8)
173.905 8.625 P = 0.165 P < 0.05 P = 0.434
SR 0.1mg + JZL184
1mg (n = 5)
194.248 14.400
Intra-NAcC SR141716 after
systemic administration of
JZL184 (Figures 1E,F)
Control (n = 7) 202.137 10.253 Two-way
ANOVA
TreatSRcore TreatJZL184ip TreatSRcoreXJZL184ip
JZL184 1mg (n = 7) 195.491 20.738 F = 0.798 F = 4.381 F = 4.871
SR141716A 3 µg (n = 6) 211.063 24.792 P = 0.381 P < 0.05 P < 0.05
SR 3 µg + JZL184 1mg
(n = 7)
209.801 19.074
Intra-NAcC SR141716 after
systemic administration of
morphine (Figures 2A,B)
Control (n = 7) 232.620 19.402 Two-way
ANOVA
TreatSRcore TreatMORsc TreatSRcorexMORsc
MOR 1mg (n = 11) 216.075 9.496 F = 1.454 F = 0.299 F = 3.498
SR141716A 3 µg (n = 7) 194.173 12.541 P = 0.236 P = 0.588 P = 0.070
SR 3 µg + MOR 1mg
(n = 12)
224.378 9.727
JZL184 + naloxone systemic
administration (Figures 2C,D)
Control (n = 8) 220.165 25.863 Two-way
ANOVA
TreatNLX TreatJZL184 TreatNLXxJZL184
JZL184 1mg (n = 9) 239.708 18.490 F = 2.282 F = 0.005 F = 0.909
NLX 1mg (n = 5) 209.500 12.638 P = 0.143 P = 0.946 P = 0.349
NLX 1mg + JZL184 1mg
(n = 8)
192.552 6.848
Intra-NAcC naloxone after
systemic administration of
JZL184 (Figures 2E,F)
Control (n = 8) 249.316 11.744 Two-way
ANOVA
TreatNLXcore TreatJZL184ip TreatNLXcorexJZL184ip
JZL184 1mg (n = 5) 246.668 8.390 F = 0.220 F = 0.080 F = 0.003
NLX 0.5 µg (n = 7) 255.579 9.650 P = 0.644 P = 0.780 P = 0.953
NLX 0.5 µg + JZL184
1mg (n = 7)
251.529 13.940
Intra-NAcC CTAP after systemic
administration of JZL184
(Figures 3A,B)
Control (n = 9) 184.429 7.776 Two-way
ANOVA
TreatCTAPcore TreatJZL184ip TreatCTAPcoreXJZL184ip
JZL184 1mg (n = 7) 219.241 11.026 F = 1.772 F = 0.9339 F = 2.894
CTAP 3 µg (n = 10) 193.263 11.840 P = 0.193 P = 0,341 P = 0.099
SR 3 µg + JZL184 1mg
(n = 9)
170.723 15.160
= 8.882, p < 0.01; Figure 2B; for complete statistical
analysis see Table 3]. Post-hoc analysis showed that the play-
enhancing effects of systemic administration of morphine
(1mg/kg) were prevented by the intra-NAcC infusion
of a dose of SR141716 that did not affect social play by
itself.
Conversely, we tested if 2-AG-induced increase in social play
required MOR in the NAcC. First, we observed that systemic
pretreatment with the MOR antagonist naloxone (1mg/kg)
30min before systemic administration of JZL184 (1 mg/kg)
prevented the play-enhancing effects of systemic administration
of JZL184 [two-way ANOVA: pinning, F(JZLxNLX) (1, 26) = 5.165,
p < 0.05; Figure 2C; pouncing, F(JZLxNLX) (1, 26) = 7.223,
p < 0.05; Figure 2D; for complete statistical analysis see
Table 3]. Post-hoc analysis revealed that JZL184 (1 mg/Kg)
increased social play when co-administered with vehicle but
not when the animals were pretreated with naloxone. In
support of our working hypothesis, we found that intra-
NAcC infusion of naloxone antagonized increase in social play
induced by systemic treatment with JZL184 (1mg/kg) [two-way
ANOVA: pinning, F(JZLsyst×NLX NAcC) (1, 23) = 5.239, p < 0.05;
Figure 2E; pouncing, F(JZLsyst×NLX NAcC) (1, 23) = 5.856, p < 0.05;
Figure 2F; for complete statistical analysis see Table 3]. Post-
hoc analysis showed that JZL184-induced increase in social play
behavior was absent in rats that received intra-NAcC naloxone.
Naloxone is only moderately selective for MORs (Goldstein
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TABLE 3 | Statistical report of social behavior parameters in adolescent rats and mice.
Treatment Social play
parameters
No. of animals for
group
Mean SEM Test ANOVA F- and P-values
JZL184 + SR141716
systemic administration
(Figures 1C,D)
Pinning
(frequency)
Control (n = 7) 35.9 1.8 Two-way
ANOVA
TreatSR TreatJZL184 TreatSRxJZL184
JZL184 1 mg/kg
(n = 7)
58.9 6.4 F = 8.194 F = 7.604 F = 6.362
SR141716 0.1
mg/kg (n = 8)
34.4 3.6 P < 0.01 P < 0.05 P < 0.05
SR 0.1 mg/kg +
JZL 1 mg/kg (n = 5)
35.4 3.8
Pouncing
(frequency)
Control (n = 7) 60.3 4.4 Two-way
ANOVA
TreatSR TreatJZL184 TreatSR x JZL184
JZL184 1 mg/kg
(n = 7)
100.3 8.3 F = 7.563 F = 12.176 F = 7.749
SR141716 0.1
mg/kg (n = 8)
60.5 3.9 P < 0.05 P < 0.01 P < 0.05
SR 0.1 mg/kg +
JZL 1 mg/kg (n = 5)
65.0 8.8
Intra-NAcC SR141716 after
systemic administration of
JZL184 (Figures 1E,F)
Pinning
(frequency)
Control (n = 7) 30.7 4.4 Two-way
ANOVA
TreatSRNAcC TreatJZL184ip TreatSRNAcC x JZL184ip
JZL184 1 mg/kg
(n = 7)
52.9 3.3 F = 3.748 F = 7.399 F = 5.496
SR141716 3 µg
(n = 6)
32.5 5.7 P = 0.06 P < 0.05 P < 0.05
SR 3 µg + JZL184
1 mg/kg (n = 7)
34.1 4.1
Pouncing
(frequency)
Control (n = 7) 67.6 9.2 Two-way
ANOVA
TreatSRNAcC TreatJZL184ip TreatSRNAcC x JZLip
JZL184 1 mg/kg
(n = 7)
104.4 6.6 F = 0.798 F = 4.381 F = 4.871
SR141716 3 µg
(n = 6)
78.8 5.4 P = 0.381 P < 0.05 P < 0.05
SR 3 µg + JZL184
1 mg/kg (n = 7)
77.9 11.0
Intra-NAcC SR141716 after
systemic administration of
morphine (Figures 2A,B)
Pinning
(frequency)
Control (n = 7) 40.3 8.3 Two-way
ANOVA
TreatSRNAcC TreatMORsc TreatSRNAcC x MORsc
MOR 1 mg/kg
(n = 11)
81.5 11.1 F = 6.029 F = 3.202 F = 8.694
SR141716A 3 µg
(n = 7)
44.6 5.3 P < 0.05 P = 0.08 P < 0.01
SR 3 µg + MOR 1
mg/kg
(n = 12)
34.5 5.6
Pouncing
(frequency)
Control (n = 7) 73.4 6.2 Two-way
ANOVA
TreatSRNAcC TreatMORsc TreatSRNAcC x MORsc
MOR 1 mg/kg
(n = 11)
131.2 13.1 F = 9.611 F = 5.795 F = 8.882
SR141716 3 µg
(n = 7)
72.1 10.6 P < 0.01 P < 0.05 P < 0.01
SR 3 µg + MOR 1
mg/kg (n = 12)
66.0 7.7
JZL184 + naloxone systemic
administration (Figures 2C,D)
Pinning
(frequency)
Control (n = 8) 18.6 3.5 Two-way
ANOVA
TreatNLX TreatJZL184 TreatNLX x JZL184
JZL184 1mg /kg
(n = 9)
40.8 2.8 F = 3.277 F = 17.918 F = 5.165
NLX 1 mg/kg
(n = 5)
20.2 4.6 P = 0.082 P < 0.001 P < 0.05
NLX 1 mg/kg + JZL
1 mg/kg (n = 8)
26.9 3.0
(Continued)
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TABLE 3 | Continued
Treatment Social play
parameters
No. of animals for
group
Mean SEM Test ANOVA F- and P-values
Pouncing
(frequency)
Control (n = 8) 53.1 4.3 Two-way
ANOVA
TreatNLX TreatJZL184 TreatNLX x JZL184
JZL184 1 mg/kg
(n = 9)
79.4 6.0 F = 2.147 F = 5.949 F = 7.223
NLX 1 mg/kg
(n = 5)
59.4 6.8 P = 0.155 P < 0.05 P < 0.05
NLX 1 mg/kg + JZL
1 mg/kg (n = 8)
58.1 2.4
Intra-NAcC naloxone after
systemic administration of
JZL184 (Figures 2E,F)
Pinning
(frequency)
Control (n = 8) 43.9 3.5 Two-way
ANOVA
TreatNLXNAcC TreatJZL184ip TreatNLXNAcC x JZLip
JZL184 1mg
(n = 5)
72.0 9.6 F = 7.871 F = 4.452 F = 5.239
NLX 0.5 µg (n = 7) 40.6 6.5 P < 0.05 P < 0.05 P < 0.05
NLX 0.5 µg +
JZL184 1mg
(n = 7)
39.4 6.6
Pouncing
(frequency)
Control (n = 8) 85.3 5.7 Two-way
ANOVA
TreatNLXNAcC TreatJZL184ip TreatNLXNAcC x JZLip
JZL184 1 mg/kg
(n = 5)
121.0 8.5 F = 15.920 F = 2.881 F = 5.856
NLX 0.5 µg (n = 7) 77.1 7.0 P < 0.001 P = 0.10 P < 0.05
NLX 0.5 µg + JZL
1 mg/kg (n = 7)
71.6 9.4
Intra-NAcC CTAP after
systemic administration of
JZL184 (Figures 3A,B)
Pinning
(frequency)
Control (n = 9) 38.9 5.9 Two-way
ANOVA
TreatCTAPNAcC TreatJZL184ip TreatCTAPNAcC x JZLip
JZL184 1 mg/kg
(n = 7)
69.0 8.3 F = 9.812 F = 2.627 F = 2.845
CTAP 3 µg (n = 10) 39.3 4.1 P < 0.01 P = 0.12 P = 0.10
SR 3 µg + JZL184
1 mg/kg (n = 9)
48.3 7.0
Pouncing
(frequency)
Control (n = 9) 71.2 8.7 Two-way
ANOVA
TreatCTAPNAcC TreatJZL184ip TreatCTAPNAcC x JZLip
JZL184 1 mg/kg
(n = 7)
114.9 10.4 F = 5.851 F = 1.103 F = 7.030
CTAP 3 µg (n = 10) 85.0 9.1 P < 0.05 P = 0.30 P < 0.05
SR 3 µg + JZL184
1 mg/kg (n = 9)
83.0 5.6
JZL184 + SR141716
systemic administration
(Figures 4C,D)
Duration (s) Control (n = 8) 101.8 7.6 Two-way
ANOVA
TreatSR TreatJZL184 TreatSR x JZL184
JZL184 8 mg/kg
(n = 8)
133.2 9.5 F = 2.516 F = 0.587 F = 6.679
SR141716 3 mg/kg
(n = 6)
111.1 5.3 P = 0.125 P =.451 P < 0.05
SR 3 mg/kg + JZL
8 mg/kg (n = 7)
94.1 12.5
Frequency Control (n = 8) 40.4 1.8 Two-way
ANOVA
TreatSR TreatJZL184 TreatSR x JZL184
JZL184 8 mg/kg
(n = 8)
54.0 3.2 F = 1.924 F = 1.747 F = 6.231
SR141716 3 mg/kg
(n = 6)
44.3 2.8 P = 0.177 P = 0.198 P < 0.05
SR 3 mg/kg + JZL
8 mg/kg (n = 7)
40.1 5.5
JZL184 + naloxone systemic
administration (Figures 4E,F)
Duration (s) Control (n = 6) 109.6 9.5 Two-way
ANOVA
TreatNLX TreatJZL184 TreatNLX x JZL184
JZL184 8 mg/kg
(n = 6)
152.8 12.5 F = 0.254 F = 1.968 F = 6.717
NLX 1 mg/kg
(n = 8)
115.6 9.7 P = 0.619 P = 0.173 P < 0.05
(Continued)
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TABLE 3 | Continued
Treatment Social play
parameters
No. of animals for
group
Mean SEM Test ANOVA F- and P-values
NLX 1 mg/kg + JZL
8 mg/kg (n = 9)
108.0 9.8
Frequency Control (n = 6) 55.8 3.0 Two-way
ANOVA
TreatNLX TreatJZL184 TreatNLX x JZL184
JZL184 8 mg/kg
(n = 6)
73.3 4.7 F = 0.627 F = 1.091 F = 3.883
NLX 1 mg/kg
(n = 8)
48.5 3.1 P = 0.435 P = 0.305 P < 0.05
NLX 1 mg/kg + JZL
8 mg/kg (n = 9)
48.7 3.7
and Naidu, 1989; Mansour et al., 1995). Therefore, to test
whether the play-enhancing effects of JZL184 were specifically
mediated by MORs, animals received systemic administration of
JZL184 followed by intra-NAcC infusion of the selective MOR
antagonist CTAP. Intra-NAcC infusion of CTAP inhibited the
effects of systemic JZL184 treatment on social play [two-way
ANOVA: pinning, F(JZLsyst×CTAP NAcC) (1, 31) = 2.845, p = 0.10;
Figure 3A; pouncing, F(JZLsyst×CTAP NAcC) (1,31) = 7.030, p <
0.05; Figure 3B; for complete statistical analysis see Table 3].
Post-hoc analysis showed that the play-enhancing effects of
systemic administration of JZL184 were prevented by intra-
NAcC infusion with a non-effective dose of CTAP.
2-AG Signaling is Involved in Social
Behavior via CB1Rs and MORs in
Adolescent Mice
Reciprocal opioid-eCB antagonism in the modulation of
social behavior also exists in adolescent mice. Systemic
administration of JZL184 to young mice increased social
interaction [one-way ANOVA: total time [F(3, 27) = 3.786,
p < 0.05; Figure 4A] and frequency [F(3, 27) = 4.693, p <
0.01; Figure 4B] of social interaction]. Post-hoc analysis revealed
that, at the dose of 8 mg/kg, JZL184 increased the total time
(Figure 4A) and frequency (Figure 4B) of social interaction
in adolescent mice. Pretreatment with the CB1R antagonist
SR141716 (3 mg/kg) 30 min before systemic administration of
JZL184 (8 mg/kg) prevented the increase in social behavior
induced by treatment with JZL184 [two-way ANOVA: total
time [F(JZLxSR) (1, 25) = 6.679, p < 0.05; Figure 4C] and
frequency [F(JZLxSR) (1, 25) = 6.231, p < 0.05; Figure 4D] of
social interaction; for complete statistical analysis see Table 3].
Post-hoc analysis revealed that JZL184 increased social behavior
when co-administered with vehicle but not in animals pretreated
with SR141716.Pretreatment with naloxone (1 mg/kg) also
antagonized the effects of systemic JZL184 (8 mg/kg) [two-way
ANOVA: total time [F(JZLxSR) (1, 25) = 6.717 p < 0.05; Figure 4E]
and frequency [F(JZLxSR) (1, 25) = 3.883, p < 0.05; Figure 4F]
of social interaction; for complete statistical analysis see
Table 3]: thus, JZL184 increased social interaction in mice
pre-treated with vehicle but not in animals that received
naloxone. This interaction was bidirectional since the social
FIGURE 4 | 2-AG elevation in adolescent mice stimulates social
behavior through CB1R and OR. JZL184 (8 mg/kg, i.p.) increased the total
time (A) and frequency (B) of social interaction. Pre-treatment with the CB1R
antagonist SR141716 (3 mg/kg, i.p.) antagonized these effects (C,D). In
addition, pre-treatment with the OR antagonist naloxone (1 mg/kg, s.c.)
prevented the effects of systemic JZL184 on social behavior (8 mg/kg, i.p.)
(E,F). Data represent mean ± S.E.M. time (A,C,E) and frequency (B,D,F) of
social interaction. *p < 0.05, **p < 0.01 vs. vehicle; $p < 0.05 vs.
vehicle/JZL184 (Student-Newman-Keuls post-hoc test). N = 7–9 per
treatment group.
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TABLE 4 | Statistical report of social behavior parameters in adolescent mice following systemic morphine.
Treatment Social interaction
parameter
No. of animals
for group
Mean SEM Test ANOVA P-value
Morphine systemic
administration (Figures 5A,B)
Duration (s) Control (n = 5) 97.808 10.394 One-way
ANOVA
F = 3.798 P < 0.05
MOR 1mg (n = 7) 126.766 11.079
MOR 3mg (n = 6) 138.747 8.328
Frequency Control (n = 5) 54.000 3.795 One-way
ANOVA
F = 4.739 P < 0.05
MOR 1mg (n = 7) 71.000 7.270
MOR 3mg (n = 6) 82.000 5.465
Morphine + naloxone systemic
administration (Figures 5C,D)
Duration (s) Control (n = 7) 90.177 7.326 Two-way
ANOVA
TreatNLX TreatMOR TreatNLXxMOR
MOR 3mg (n = 6) 134.640 10.501 F = 9.973 F = 8.904 F = 7.173
NLX 1mg (n = 6) 86.410 6.157 P < 0.01 P < 0.01 P < 0.05
MOR 3mg + NLX
1mg (n = 5)
88.810 5.456
Frequency Control (n = 7) 47.571 5.584 Two-way
ANOVA
TreatNLX TreatMOR TreatNLXxMOR
MOR 3mg (n = 6) 84.833 3.851 F = 3.067 F = 14.634 F = 4.830
NLX 1mg (n = 6) 50.333 7.999 P = 0.09 P < 0.01 P < 0.05
MOR 3mg + NLX
1mg (n = 5)
60.400 6.539
Morphine + SR141716 systemic
administration (Figures 5E,F)
Duration (s) Control (n = 6) 105.093 11.579 Two-way
ANOVA
TreatSR TreatMOR TreatSRxMOR
MOR 3mg (n = 6) 161.427 13.114 F = 2.243 F = 5.555 F = 3.938
SR141716 3mg
(n = 6)
111.117 5.315 P = 0.149 P < 0.05 P < 0.05
MOR 3mg + SR
3mg (n = 7)
116.309 17.066
Frequency Control (n = 6) 71.833 7.888 Two-way
ANOVA
TreatSR TreatMOR TreatSRxMOR
MOR 3mg (n = 6) 115.167 14.460 F = 8.948 F = 10.51 F = 1.378
SR141716 3mg
(n = 6)
54.000 3.642 P < 0.01 P < 0.01 P = 0.253
MOR 3mg + SR
3mg (n = 7)
74.286 9.817
interaction-enhancing effects of morphine were blocked by
systemic administration of naloxone or SR141716 (Figure 5; for
statistical analysis see Table 4).
Inhibitory CB1R and MOR Interact in the
NAcC of Adolescent Rats and Mice
We next searched for synaptic underpinnings of the CB1R/MOR
interaction in the NAcC. Whole cell recordings of miniature
excitatory postsynaptic currents (mEPSCs) revealed that,
like CB1Rs, MORs act presynaptically to inhibit excitatory
transmission onto NAcC neurons (Figure 6). We next
investigated the functional relationship between these two
inhibitory presynaptic receptors (Figures 7, 9). In adolescent
rat NAcC slices, CB1R antagonism blocked the inhibitory effect
of a maximally effective concentration of the MOR agonist
DAMGO on excitatory field synaptic responses (fEPSP; p <
0.01; Figure 7C left panel; for DAMGO full dose-response see
Figure 8A). Likewise, the maximal inhibitory effect of the CB1R
agonist CP55940 on fEPSP was significantly reduced by the
MOR antagonist naloxone (p < 0.05; Figure 7C right panel; for
CP55940 full dose-response see Figure 8B). Thus, both CB1R
and MOR signaling are required for the effects of both eCBs and
opioids in the NacC.
We next relied on mouse genetics to test whether the function
of either MORs or CB1Rs depends on the presence of the other
receptor. We first verified that reciprocal opioid-cannabinoid
antagonism existed in the mouse NAcC. In WT littermates of
CB1R−/− mice, CB1R antagonist AM251 significantly reduced
DAMGO-induced inhibition of fEPSP (p < 0.01; Figure 9A).
Likewise, the MOR antagonist naloxone reduced CP55940-
induced inhibition of fEPSP in WT littermates of MOR−/−
mice (p < 0.05; Figure 9B), demonstrating that the CB1R-MOR
interaction is a feature shared by mice and rats. In marked
contrast with the WT phenotype, the CB1R antagonist AM251
lost its effect on the DAMGO-induced inhibition of fEPSP in
CB1R−/− mice (Figure 9A; n.s.), showing that opioid-induced
inhibition of fEPSP occurs through CB1Rs. Interestingly, the
MOR agonist DAMGO was less effective in reducing excitatory
transmission in CB1R−/− mice (p < 0.05; Figure 9A), indicating
that the expression of CB1R is necessary for the full inhibitory
effect of DAMGO. Likewise, the MOR antagonist naloxone did
not antagonize eCB-induced inhibition of fEPSP in MOR−/−
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FIGURE 5 | Morphine stimulates social play in adolescent mice via OR
and CB1R activation. The OR agonist morphine (3 mg/kg, s.c.) increased
the total time (A) and frequency (B) of social interaction. Pre-treatment with
the OR antagonist naloxone (1 mg/kg, s.c.) prevented the social
interaction-enhancing effects of systemic morphine (C,D). Likewise,
pre-treatment with the CB1R antagonist SR141716 (3 mg/kg, i.p.)
antagonized morphine’s effects on social interaction (E,F). Data represent
mean ± S.E.M. time (A,C,E) and frequency (B,D,F) of social interaction. *p <
0.05 vs. vehicle; $p < 0.05 vs. vehicle/morphine (Student-Newman-Keuls
post-hoc test). N = 7–10 per treatment group.
mice (Figure 9B; n.s.) showing that CB1R-induced inhibition of
fEPSP occurs through MORs in the NAcC.
DISCUSSION
The present study supports the idea that CB1R and MOR
interact in the NAcC to underlie the actions of endogenous
cannabinoid lipids and opioid peptides on social behavior in
adolescent rats and mice. Social play is one of the earliest forms
of non-mother directed social behavior observed in mammals.
It contains behavioral patterns related to social, sexual and
aggressive behavior (Vanderschuren et al., 1997; Trezza et al.,
2010). During post-weaning development, social play is mostly
directed at conspecifics and the ability to engage in social play
is one of the principal indicators of healthy development. The
endocannabinoid system participates in emotional homeostasis
from early developmental stages onwards (Viveros et al., 2007;
Solinas et al., 2008; Berridge et al., 2010; Campolongo et al.,
2011). In adolescent rats, anandamide promotes social play
via CB1R in the basolateral amygdala (Trezza et al., 2012)
and in adult mice it mediates oxytocin-driven social reward
via CB1R located in the NAc (Wei et al., 2015). The main
endocannabinoid 2-AG is released in the brain of adolescent rats
during social play (Manduca et al., 2015), although the exact
brain region where 2-AG modulates social play was unknown.
Furthermore, 2-AG levels have been shown to be higher in
the NAc of socially stimulated mice compared to isolated mice
(Wei et al., 2016), and 2-AG decreases aggressive behavior
in a resident/intruder test in adult mice, suggesting a role in
social challenge (Aliczki et al., 2014). In the present study, we
found that JZL184, which produces a long-lasting elevation of
brain 2-AG by inhibiting MAGL mediated 2-AG hydrolysis
(Long et al., 2009; Seillier et al., 2014; Morena et al., 2015),
increased the frequency of pinning and pouncing, the two
principal characteristic parameters of social play in adolescent
rats. Our data unequivocally demonstrate that 2-AG stimulated
social play depending upon activation of CB1R in the NAcC.
Thus both anandamide and 2-AG participate in social reward
(Marco et al., 2011; Trezza et al., 2012; Wei et al., 2015, 2016)
and social play (Trezza et al., 2012). The endogenous opioid
system bidirectionally modulates social behavior in adolescent
rats: accumbens MOR and κ-opioid receptors stimulate and
inhibit social play, respectively (Trezza et al., 2011b). With
respect to the eCB system we previously reported that the play-
stimulating properties of anandamide were inhibited by opioid
antagonism, and vice versa (Trezza and Vanderschuren, 2008a,
2009). Specifically, we showed that the anandamide hydrolysis
inhibitor URB597 enhanced social play. This effect was blocked
by pretreatment with the OR antagonist naloxone, and the well-
known stimulatory effect ofmorphine on social play behavior was
attenuated by pretreatment with the CB1R antagonist SR141716
(Trezza and Vanderschuren, 2008a, 2009). Here, we demonstrate
that the 2-AG-induced increase in social play requires MOR in
the NAcC: infusion of either naloxone or the selective MOR
antagonist CTAP into the NAcC prevented the play-enhancing
effects of JZL184. Thus, 2-AG modulates social play through
stimulation of both CB1R and MOR in the NAcC. Strikingly, this
interaction was bidirectional: the increase in social play induced
by systemic treatment with the OR agonist morphine was blocked
by intra-NAcC CB1R inhibition. These data suggest a reciprocal
interaction between eCB lipid and opioid peptide systems in the
NAcC to regulate social play behavior. Previous findings reported
the importance of NAcC in social play (Trezza et al., 2011b;
Manduca et al., 2016) and the role of opioids and eCBs in the
modulation of social play in this brain structure (Trezza et al.,
2011b, 2012). However, to the best of our knowledge, this is
the first study showing a close relationship between CBR1 and
MOR specifically in the NAcC in the modulation of social play
behavior. Importantly, our present data extend the role of opioid-
eCB interactions in the modulation of social interaction to social
interaction in youngmice. In contrast to rats, in which social play
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FIGURE 6 | Presynaptic inhibitory CB1 and MOR interact at excitatory NAcC synapses. To localize the inhibitory action of DAMGO on excitatory NAcC
synapses, we recorded miniature EPSCs by whole cell recordings in NAcC medium spiny neurons (MSN) clamped at –70 mV. mEPSC frequency and amplitude were
calculated in the 10-min interval before and after 20 min of bath application of 10 µM DAMGO. Effect of DAMGO on miniature excitatory events in NAcC MSN: (A)
Representative mEPSC of recordings before (control) and after DAMGO bath application; (B) Cumulative probability distribution of intervals between events showing a
shift to the right after DAMGO and the length of inter-event interval was markedly increased [Kolmogorov-Smirnov (K-S), p < 0.001]; (C) Lower mean mEPSC
frequency but no change in mean amplitude after DAMGO (N = 9 for both groups, *p < 0.05 by paired t-test); (D) Cumulative probability distribution of mEPSC
amplitude showing no change. The cumulative distribution [(K-S) test; n.s.] and mean amplitude of the mEPSC remained unchanged after DAMGO application (CTRL:
mean 13.46 ± 1.2 pA; DAMGO: mean 12.28 ± 0.99 pA; paired t-test). Error bars represent S.E.M.
behavior is easy to distinguish from non-playful social behavior
(Panksepp and Beatty, 1980; Vanderschuren et al., 1997), social
play behavior is hard to recognize as such in mice (Pellis
and Pasztor, 1999). Therefore, we can not say with confidence
whether the nature of the social behavior in mice reported here
is strictly playful. Nevertheless, the fact that social interaction in
young mice is modulated by two interacting neurotransmitter
systems that have been widely implicated in reward processes
(Van Ree et al., 2000; Solinas et al., 2008; Le Merrer et al., 2009;
Berridge and Kringelbach, 2015), strongly suggests that this social
behavior in young mice has positive emotional value.
In vivo studies have previously shown that genetic deletion
of CB1R reduces morphine self-administration and attenuates
morphine-induced conditioned place preference (Chaperon
et al., 1998; Ledent et al., 1999; Navarro et al., 2001; Caille
and Parsons, 2003; Solinas et al., 2003), indicating that
functional CB1Rs are required for the rewarding effects of
opiates. Biochemical evidence of interactions between CB1Rs
and MORs are abound (Shapira et al., 2000; Salio et al., 2001;
Hojo et al., 2008): in vitro bioluminescence resonance energy
transfer showed CB1R hetero-oligomerizing with MOR (Rios
et al., 2006) and CB1R/MOR interaction were found in FRET
and co-immunoprecipitation experiments in expression cell
models (Hojo et al., 2008). Finally, neurochemical data have
indicated that allosterically-interacting MOR and CB1R control
neurotransmitter release in the NAcC (Schoffelmeer et al., 2006).
In line with these results, we report electrophysiological evidence
of opioid-cannabinoid antagonism at excitatory NAcC synapses
of mice and rats where CB1R are located on axon terminals
contacting NAcC medium spiny neurons (Robbe et al., 2001;
Pickel et al., 2004) while MOR are found both pre- and post-
synaptically (Hoffman et al., 2003; Pickel et al., 2004). Here, we
found that the effects of the CB1R antagonist on opioid-induced
inhibition of fEPSP were lost in CB1R−/− mice while naloxone
did not antagonize CB1R in MOR−/− mice. Furthermore, the
MOR agonist DAMGO was less efficient in CB1R−/− mice,
indicating that CB1R are necessary for the full inhibitory effect
of DAMGO.
Collectively, the data support the idea that these two cognate
presynaptic receptors interact, perhaps within a heterodimer
complex, to underlie eCB and opioid effects in the NAcC and
provide a plausible substrate for the heterologous interaction
between MOR and CB1R in the regulation of positively valenced
social behavior in rodents. Further, understanding of the neural
mechanisms of rewarding social interactionsmay help to increase
knowledge about the physiological mechanisms of adaptive social
development, as well as of the mental disorders characterized by
aberrant social behavior.
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FIGURE 7 | Presynaptic inhibitory CB1R and MOR interact in the NAcC.
Representative field potential responses (fEPSP) before (baseline) and after
drug application (arrow) (A,B). The CB1R antagonist AM251 blocked the
fEPSP inhibition induced by the selective MOR agonist DAMGO in rat NAcC
slices (C, left panel). Conversely, the OR antagonist naloxone prevented the
inhibition of fEPSP induced by the CB1R agonist CP55940 in rat NAcC slices
(C, right panel). Data represent mean ± S.E.M. percent fEPSP inhibition after
drug application. *p < 0.05; **p < 0.01 vs. DAMGO and CP55940. N = 5–8
per treatment group.
FIGURE 8 | Dose response curves for inhibition by MOR and CB1R
agonists at excitatory NAcC synapses. Dose response curve for the MOR
agonist DAMGO (A) and for the CB1R agonist CP55940 (B) in rats. Error bars
represent S.E.M. N = 3–5 per doses.
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